Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

New products drive growth in 2016

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $18.1 billion (+2%)

4Q Earnings: $3.8 billion (+19%)

FY Revenues: $71.9 billion (+3%)

FY Earnings: $16.5 billion (+7%)

Comments: Worldwide Pharmaceutical sales were $33.5 billion for the year, up 7%. Domestic sales increased 10% and international sales increased 2%. Strong growth in new products include IMBRUVICA ($1.3 billion, up 82%), for use in treating certain B-cell malignancies; DARZALEX ($572 million), for the treatment of multiple myeloma; XARELTO ($2.3 billion, up 23%), an oral anticoagulant, and INVOKANA/INVOKAMET ($1.4 billion, up 8%) for the treatment of type 2 diabetes. Growth drivers also included STELARA ($3.2 billion, up 31%), REMICADE ($7.0 billion, up 6%), and SIMPONI/SIMPONI ARIA ($1.7 billion, up 31%), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; INVEGA SUSTENNA ($2.2 billion, up 21%) long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults and EDURANT ($573 million, up 40%) for the treatment of HIV. Sales were negatively impacted by generic competition for ORTHO TRI-CYCLEN LO, oral contraceptive and INVEGA (down 46% to $311 million), long-acting, injectable for the treatment of schizophrenia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters